Drug intelligence / Profile preview

infliximab-epirus

Development stage: Phase 3
Lead developer: Epirus Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Infliximab-epirus is a biosimilar of infliximab, a chimeric (human-murine) monoclonal IgG1 antibody that binds with high affinity to tumor necrosis factor alpha (TNF-α), a key pro-inflammatory cytokine. By neutralizing both the soluble and transmembrane forms of TNF-α, infliximab-epirus inhibits the inflammatory cascade involved in a variety of autoimmune diseases, such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Infliximab-epirus was developed by Epirus Biopharmaceuticals as BOW015 and received regulatory approval in India as a "similar biologic" to Remicade (infliximab)[6][1].

Brand names: Infimab
Other names: infliximab-epirusBOW015BOW-015BOW 015

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on infliximab-epirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on infliximab-epirus.

Explore the full profile